AbbVie Apogee Deal Highlights Decade of Pharma M&A
AbbVie has reached an agreement to acquire Apogee Therapeutics for $10.9 billion in cash to strengthen its immunology pipeline. This transaction joins a significant list of high-value pharmaceutical mergers and acquisitions over the past decade targeting oncology, neurology, and rare diseases.
Xurve View
洞察:
Xurve View
ABBVIE INC agreed to acquire APOGEE THERAPEUTICS INC for $10.9 billion in cash midday June 22. The deal targets next-generation immunology treatments to bolster the drugmaker's pipeline. This acquisition marks the latest in a decade-long wave of multi-billion dollar consolidations within the United States pharmaceutical sector.
